BB BIOTECH BB Biotech AG publishes its interim report
Transparency directive : regulatory news
|
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report Media release of July 24, 2020 Interim report of BB Biotech AG as at June 30, 2020 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2020, which covers the results of its business activities for the first six months of 2020. Based on the consolidated accounts of BB Biotech AG, net profit for the period ended June 30, 2020 amounted to CHF 422 mn (profit of CHF 554 mn in H1 2019). In the second quarter a profit of CHF 1'180 mn (loss of CHF 336 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio. BB Biotech AG's interim report as at June 30, 2020 can be downloaded at www.bbbiotech.com.
Company profile Disclaimer
24-Jul-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | info@bbbiotech.com |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX |
| EQS News ID: | 1100723 |
| End of Announcement | DGAP News Service |
|
|
1100723 24-Jul-2020 CET/CEST